Education
About Us
Working with TipRanks
Follow Us
PJP - ETF AI Analysis
Top Page
Invesco Dynamic Pharmaceuticals ETF (PJP)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Large-Cap Pharma Holdings
Several major drug companies in the top holdings have shown solid gains this year, helping support the fund’s overall performance.
Recent Short-Term Momentum
The ETF has delivered strong performance over the last three months, indicating improving short-term momentum despite a weak year-to-date result.
Focused Exposure to U.S. Health Care
Almost all assets are invested in U.S. health care companies, giving targeted exposure to a defensive sector that can be more resilient in economic slowdowns.
Negative Factors
High Sector Concentration
Nearly all of the fund is invested in health care, so it could be hit hard if the pharmaceutical industry faces regulatory or pricing pressures.
Mixed Performance Among Top Holdings
A few sizable positions, such as Abbott and AbbVie, have been weak this year, which can drag on the ETF’s overall returns.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are eaten up by fees over time.
PJP vs. SPDR S&P 500 ETF (SPY)
AUM398.52M
RegionNorth America
Expense Ratio0.57%
Beta0.56
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield0.97%
Asset ClassEquity
Index TrackedDynamic Pharmaceutical Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume23,314
30 Day Avg. Volume37,909
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
128.89Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PJP Summary
PJP is the Invesco Dynamic Pharmaceuticals ETF, which follows the Dynamic Pharmaceutical Intellidex Index and focuses on U.S. drug and health care companies. It holds well-known names like Merck and Johnson & Johnson, along with other major pharmaceutical firms. Someone might invest in PJP to tap into the long-term growth potential of new medicines and an aging population, while still spreading money across many companies instead of picking just one stock. A key risk is that it is heavily concentrated in the pharmaceutical sector, so its price can swing with drug news, regulations, and health care policy changes.
How much will it cost me?The Invesco Dynamic Pharmaceuticals ETF (PJP) has an expense ratio of 0.57%, meaning you’ll pay $5.70 per year for every $1,000 invested. This cost is higher than average because it’s actively managed, focusing on selecting pharmaceutical stocks based on various strategic factors to optimize performance.
What would affect this ETF?The Invesco Dynamic Pharmaceuticals ETF (PJP) could benefit from advancements in drug discovery, regulatory approvals, and the growing demand for pharmaceuticals driven by an aging population. However, it may face challenges from stricter regulations, patent expirations, or pricing pressures in the U.S. market, where it is heavily focused. The performance of its top holdings, such as AbbVie and Eli Lilly, will also play a significant role in shaping its future returns.
PJP Top 10 Holdings
PJP is a pure play on U.S. big pharma, with the fund’s story largely written by heavyweights like Merck, Johnson & Johnson, Pfizer, Amgen, and Eli Lilly. Merck and J&J have been rising steadily, helping to pull the ETF higher, while Eli Lilly’s strong recent run has been a key engine of momentum. Smaller name Liquidia has been sprinting ahead, adding a speculative spark. On the flip side, Abbott and AbbVie have been lagging, acting as a bit of a brake on an otherwise solid health care convoy.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Gilead Sciences | 5.72% | $22.97M | $176.11B | 46.04% | 78 Outperform | |
| Johnson & Johnson | 5.56% | $22.34M | $547.51B | 49.36% | 78 Outperform | |
| Merck & Company | 5.54% | $22.26M | $273.69B | 11.59% | 80 Outperform | |
| Pfizer | 5.29% | $21.25M | $150.33B | -0.30% | 74 Outperform | |
| Amgen | 5.16% | $20.74M | $184.10B | 19.78% | 77 Outperform | |
| AbbVie | 4.90% | $19.69M | $394.14B | 21.27% | 66 Neutral | |
| Eli Lilly & Co | 4.90% | $19.68M | $980.50B | 27.87% | 72 Outperform | |
| Abbott Laboratories | 4.33% | $17.42M | $190.06B | -14.56% | 73 Outperform | |
| Liquidia Technologies | 3.96% | $15.93M | $3.69B | 197.89% | 57 Neutral | |
| Viatris | 3.46% | $13.90M | $15.08B | 16.05% | 60 Neutral |
PJP Technical Analysis
Positive
―
Price Trends
105.29
Negative
99.93
Positive
91.15
Positive
Market Momentum
0.11
Positive
50.61
Neutral
55.95
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 105.10, equal to the 50-day MA of 105.29, and equal to the 200-day MA of 91.15, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 55.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PJP.
PJP Peer Comparison
Comparison Results
Performance Comparison
PJP
Invesco Dynamic Pharmaceuticals ETF
105.26
20.36
23.98%
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents